Form 8-K - Current report:
SEC Accession No. 0000950170-24-139633
Filing Date
2024-12-23
Accepted
2024-12-23 16:42:08
Documents
15
Period of Report
2024-12-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atyr-20241224.htm   iXBRL 8-K 57647
2 EX-1.1 atyr-ex1_1.htm EX-1.1 33637
3 EX-5.1 atyr-ex5_1.htm EX-5.1 30728
4 GRAPHIC img54294278_0.jpg GRAPHIC 29364
5 GRAPHIC img54294278_1.jpg GRAPHIC 29364
  Complete submission text file 0000950170-24-139633.txt   330232

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atyr-20241224.xsd EX-101.SCH 26206
18 EXTRACTED XBRL INSTANCE DOCUMENT atyr-20241224_htm.xml XML 4710
Mailing Address 10240 SORRENTO VALLEY ROAD SUITE 300 SAN DIEGO CA 92121
Business Address 10240 SORRENTO VALLEY ROAD SUITE 300 SAN DIEGO CA 92121 8587318389
aTYR PHARMA INC (Filer) CIK: 0001339970 (see all company filings)

EIN.: 203435077 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37378 | Film No.: 241574362
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)